黄芪活性成分改善糖尿病肾病脂代谢紊乱的研究进展

郑丽萍 ,  朱晗 ,  赵克勤 ,  黄勇 ,  刘鹏

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 928 -936.

PDF (1247KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 928 -936. DOI: 10.12092/j.issn.1009-2501.2026.07.009
综述与讲座

黄芪活性成分改善糖尿病肾病脂代谢紊乱的研究进展

作者信息 +

Research progress of active components of Astragalus membranaceus in improving lipid metabolism disorder of diabetic kidney disease

Author information +
文章历史 +
PDF (1276K)

摘要

糖尿病肾病 (diabetic kidney disease,DKD)是一种继发于糖尿病的常见微血管并发症。其发病率呈现逐年增加的趋势,严重威胁糖尿病患者的预后和生活质量。目前临床上对于DKD 的治疗选择有限,难以有效阻止其进展。在DKD 复杂的病理生理机制中,脂代谢紊乱扮演着重要角色,不仅促进肾内脂质沉积,还通过脂毒性加速肾脏损伤进程。近年来,中草药因其在改善DKD 脂代谢紊乱方面具有显著效果而备受关注。黄芪是治疗 DKD 的常用中草药,在 DKD 的治疗中表现出显著的肾脏保护作用。黄芪富含黄芪甲苷Ⅳ、芒柄花素、槲皮素、山奈酚等活性成分,在改善 DKD 脂代谢紊乱方面展现出独特优势,其不仅可以有效改善脂代谢异常,还可以减少肾脏脂质沉积。 本文系统综述了黄芪活性成分改善DKD 脂代谢紊乱的作用研究进展,为临床治疗DKD 策略提供理论依据。

Abstract

Diabetic kidney disease (DKD) is a common microvascular complication secondary to diabetes. Its incidence is increasing year by year, which seriously threatens the prognosis and quality of life of diabetic patients. At present, the clinical treatment options for DKD are limited, and it is difficult to effectively prevent its progression. In the complex pathophysiological mechanism of DKD, lipid metabolism disorder plays an important role, which not only promotes lipid deposition in the kidney, but also accelerates the process of renal injury through lipid toxicity. In recent years, Chinese herbal medicine has attracted much attention because of its significant effect in improving DKD lipid metabolism disorder. Astragalus membranaceus is a commonly used Chinese herbal medicine for the treatment of DKD, which shows significant renal protective effect in the treatment of DKD. Astragalus membranaceus is rich in Astragaloside Ⅳ, formononetin, quercetin, kaempferol and other active ingredients. It shows unique advantages in improving DKD lipid metabolism disorders. It can not only effectively improve lipid metabolism disorders, but also reduce renal lipid deposition. This article systematically reviews the research progress of the effect of Astragalus active ingredients on improving lipid metabolism disorders in DKD, and provides a theoretical basis for clinical treatment of DKD strategies.

关键词

糖尿病肾病 / 黄芪 / 活性成分 / 脂代谢紊乱 / 中草药

Key words

diabetic kidney disease / Astragalus membranaceus / active ingredients / lipid homeostasis / Chinese herbal medicine

引用本文

引用格式 ▾
郑丽萍,朱晗,赵克勤,黄勇,刘鹏. 黄芪活性成分改善糖尿病肾病脂代谢紊乱的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(7): 928-936 DOI:10.12092/j.issn.1009-2501.2026.07.009

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Liu D, Chen X, He W, et al. Update on the pathogenesis, diagnosis, and treatment of diabetic tubulopathy[J].Integr Med Nephrol Androl, 2024, 11(4): e23.

[2]

Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract, 2022, 183: 109119.

[3]

Uma A, Sivaraman S, Manoharan R, et al. Diabetic kidney disease in type 2 diabetes: a comprehensive review of epidemiology, pathophysiology, and therapeutic advances[J].J Pharm Bioallied Sci, 2025, 17(2): 33-35.

[4]

Zhao H, Li Z, Yan M, et al. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle[J].J Transl Intern Med, 2024, 12(2): 157-169.

[5]

Wang X, Liu J, Liu T, et al. Discovery of the pharmacodynamic material basis of Danggui Buxue Decoction in the treatment of diabetic kidney disease based on lipidomics regulation[J].Phytomedicine, 2025, 141: 156643.

[6]

Deng Y, Zhu H, Xing J, et al. The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease[J].Front Physiol, 2025, 16: 1624077.

[7]

Zhao H, Zhao T, Li P.Gut microbiota-derived metabolites: a new perspective of traditional chinese medicine against diabetic kidney disease[J].Integr Med Nephrol Androl, 2024, 11(2): e23.

[8]

Guo MF, Dai YJ, Gao JR, et al. Uncovering the mechanism of astragalus membranaceus in the treatment of diabetic nephropathy based on network pharmacology[J].J Diabetes Res, 2020, 2020: 1-13.

[9]

Zhu Z, Zhang Q, Liu L, et al. Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: protocol for a systematic review and meta-analysis[J].Medicine (Baltimore), 2022, 101(49): e31490.

[10]

Liu J, Yang K, Zhou L, et al. A new strategy for Astragaloside Ⅳ in the treatment of diabetic kidney disease: analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells[J].Int Immunopharmacol, 2024, 141: 112794.

[11]

Chen Q, Su Y, Ju Y, et al. Astragalosides Ⅳ protected the renal tubular epithelial cells from free fatty acids-induced injury by reducing oxidative stress and apoptosis[J].Biomed Pharmacother, 2018, 108: 679-686.

[12]

Wang Y, Liu T, Wu Y, et al. Lipid homeostasis in diabetic kidney disease[J].Int J Biol Sci, 2024, 20(10): 3710-3724.

[13]

Mitrofanova A, Burke G, Merscher S, et al. New insights into renal lipid dysmetabolism in diabetic kidney disease[J].World J Diabetes, 2021, 12(5): 524-540.

[14]

Huang Y, Xu W, Zhou R.NLRP3 inflammasome activation and cell death[J].Cell Mol Immunol, 2021, 18(9): 2114-2127.

[15]

Han JH.Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling[J].Cell Commun Signal, 2025, 23(1): 373.

[16]

Li X, Dong X, Zhang L, et al. Astragaloside Ⅳ attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation[J].Front Pharmacol, 2024, 15: 1285797.

[17]

Xing L, Guo H, Meng S, et al. Klotho ameliorates diabetic nephropathy by activating Nrf2 signaling pathway in podocytes[J].Biochem Biophys Res Commun, 2021, 534: 450-456.

[18]

Li Y, Xue M, Hu F, et al. Klotho prevents epithelial-mesenchymal transition through Egr-1 downregulation in diabetic kidney disease[J].BMJ Open Diab Res Care, 2021, 9(1): e002038.

[19]

Yu LX, Sha MY, Chen Y, et al. Potential application of Klotho as a prognostic biomarker for patients with diabetic kidney disease: a Meta-analysis of clinical studies[J].Ther Adv Chronic Dis, 2023, 14: 20406223231213246.

[20]

He J, Cui J, Shi Y, et al. Astragaloside Ⅳ attenuates high-glucose-induced impairment in diabetic nephropathy by increasing klotho expression via the NF-κB/NLRP3 axis[J].J Diabetes Res, 2023, 2023: 1-22.

[21]

Liu J, Ren J, Zhou L, et al. Proteomic and lipidomic analysis of the mechanism underlying Astragaloside Ⅳ in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease[J].J Ethnopharmacol, 2024, 334: 118517.

[22]

Huang Q, Chen H, Yin K, et al. Formononetin attenuates renal tubular injury and mitochondrial damage in diabetic nephropathy partly via regulating Sirt1/PGC-1α pathway[J].Front Pharmacol, 2022, 13: 901234.

[23]

Wu W, Wang X, Yu X, et al. Smad3 signatures in renal inflammation and fibrosis[J].Int J Biol Sci, 2022, 18(7): 2795-2806.

[24]

Derynck R, Budi EH.Specificity, versatility, and control of TGF-β family signaling[J].Sci Signal, 2019, 12(570): eaav5183.

[25]

Liu P, Wang C, Wang Y, et al. Zishen Qingre Tongluo Formula improves renal fatty acid oxidation and alleviated fibrosis via the regulation of the TGF-β 1/Smad3 signaling pathway in hyperuricemic nephrology rats[J].Biomed Res Int, 2021, 2021(1): 2793823.

[26]

Dong L, Yu L, Zhong J.Histone lysine-specific demethylase 1 induced renal fibrosis via decreasing sirtuin 3 expression and activating TGF-β1/Smad3 pathway in diabetic nephropathy[J].Diabetol Metab Syndr, 2022, 14(1): 2.

[27]

Hong Q, Kim H, Cai GY, et al. Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy[J].Int J Biol Sci, 2025, 21(4): 1649-1665.

[28]

Ji X, Wang H, Wu Z, et al. Specific inhibitor of Smad3 (SIS3) attenuates fibrosis, apoptosis, and inflammation in unilateral ureteral obstruction kidneys by inhibition of transforming growth factor β (TGF-β)/Smad3 signaling[J].Med Sci Monit, 2018, 24: 1633-1641.

[29]

Lv J, Zhuang K, Jiang X, et al. Renoprotective effect of formononetin by suppressing Smad3 expression in Db/Db mice[J].Diabetes Metab Syndr Obes, 2020, 13: 3313-3324.

[30]

Lai W, Wang B, Huang R, et al. Ferroptosis in organ fibrosis: from mechanisms to therapeutic medicines[J].J Transl Intern Med, 2024, 12(1): 22-34.

[31]

He F, Ru X, Wen T.NRF2, a Transcription factor for stress response and beyond[J].Int J Mol Sci, 2020, 21(13): 4777.

[32]

Neagu M, Constantin C, Surcel M, et al. Diabetic neuropathy: a NRF2 disease ?[J].J Diabetes, 2024, 16(9): e13524.

[33]

Chen M, Chen Y, Zhu W, et al. Advances in the pharmacological study of Chinese herbal medicine to alleviate diabetic nephropathy by improving mitochondrial oxidative stress[J].Biomed Pharmacother, 2023, 165: 115088.

[34]

Chen R, Zeng J, Li C, et al. Fraxin promotes the activation of Nrf2/ARE pathway via increasing the expression of Connexin43 to ameliorate diabetic renal fibrosis[J].Front Pharmacol, 2022, 13: 853383.

[35]

Zhuang K, Jiang X, Liu R, et al. Formononetin activates the Nrf2/ARE signaling pathway via Sirt1 to improve diabetic renal fibrosis[J].Front Pharmacol, 2021, 11: 616378.

[36]

Yang T, Hu Y, Jiang W, et al. YY1 was indispensable for the alleviation of quercetin on diabetic nephropathy-associated tubulointerstitial inflammation[J].Phytomedicine, 2023, 111: 154659.

[37]

Chandrasekaran P, Weiskirchen R.The role of SCAP/SREBP as central regulators of lipid metabolism in hepatic steatosis[J].Int J Mol Sci, 2024, 25(2): 1109.

[38]

Xu ZE, Chen Y, Huang A, et al. Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA triple knockout mice[J].Am J Physiol Renal Physiol, 2011, 301(4): F713-F722.

[39]

Bai X, Wang S, Shu L, et al. Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-ⅡA signaling in macrophages in mice[J].J Ethnopharmacol, 2024, 327: 118006.

[40]

Jiang X, Yu J, Wang X, et al. Quercetin improves lipid metabolism via SCAP-SREBP2-LDLr signaling pathway in early stage diabetic nephropathy[J].Diabetes Metab Syndr Obes, 2019, 12: 827-839.

[41]

Zheng X, Zhong Q, Lin X, et al. Transforming growth factor-β1-induced podocyte injury is associated with increased microRNA-155 expression, enhanced inflammatory responses and MAPK pathway activation[J].Exp Ther Med, 2021, 21(6): 620.

[42]

Kulkarni AR, Bale CB, Wakhare PS, et al. Study of the urinary TGF-β1 profile in diabetic nephropathy: a single-center experience from India[J].Cureus, 2023, 15(9): e45102.

[43]

Anil Kumar P, Welsh GI, Saleem MA, et al. Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus[J].Front Endocrinol, 2014, 5: 141.

[44]

Jiang L, Cui H, Ding J.Smad3 signalling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin[J].Nephrology, 2020, 25(9): 659-666.

[45]

Ying Q, Wu G.Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update[J].Ren Fail, 2017, 39(1): 474-483.

[46]

Li Y, Chen S, Tan J, et al. Combination therapy with DHA and BMSCs suppressed podocyte injury and attenuated renal fibrosis by modulating the TGF-β 1/Smad pathway in MN mice[J].Ren Fail, 2023, 45(1): 2120821.

[47]

Gao F, He X, Liang S, et al. Quercetin ameliorates podocyte injury via inhibition of oxidative stress and the TGF-β1/Smad pathway in DN rats[J].RSC Adv, 2018, 8(62): 35413-35421.

[48]

Nowacka A, Śniegocka M, Śniegocki M, et al. Sirtuins in central nervous system tumors-molecular mechanisms and therapeutic targeting[J].Cells, 2025, 14(14): 1113.

[49]

Tovar-Palacio C, Noriega LG, Mercado A. Potential of polyphenols to restore SIRT1 and NAD+ metabolism in renal disease[J].Nutrients, 2022, 14(3): 653.

[50]

Nguyen LT, Mak CH, Chen H, et al. SIRT1 attenuates kidney disorders in male offspring due to maternal high-fat diet[J].Nutrients, 2019, 11(1): 146.

[51]

Zhang L, Chen Z, Gong W, et al. Paeonol ameliorates diabetic renal fibrosis through promoting the activation of the Nrf2/ARE pathway via up-regulating Sirt1[J].Front Pharmacol, 2018, 9: 512.

[52]

Jin Q, Liu T, Qiao Y, et al. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols[J].Front Immunol, 2023, 14: 1185317.

[53]

Ali M, Hassan M, Ansari SA, et al. Quercetin and kaempferol as multi-targeting antidiabetic agents against mouse model of chemically induced type 2 diabetes[J].Pharmaceuticals (Basel), 2024, 17(6): 757.

[54]

Ge X, Wang L, Fei A, et al. Research progress on the relationship between autophagy and chronic complications of diabetes[J].Front Physiol, 2022, 13: 956344.

[55]

Huang Y, Xia X, Xu J, et al. Mitophagy as a pivotal axis in non-alcoholic fatty liver disease: From pathogenic mechanisms to therapeutic strategies (Review)[J].Mol Med Rep, 2025, 32(5): 1-15.

[56]

Selim SM, El Fayoumi HM, El-Sayed NM, et al. Alogliptin attenuates STZ-induced diabetic nephropathy in rats through the modulation of autophagy, apoptosis, and inflammation pathways: Targeting NF-κB and AMPK/mTOR pathway[J].Life Sci, 2025, 361: 123307.

[57]

Guo J, Wu Y, Wan Z, et al. Post-translational modifications orchestrate mTOR-driven cell death in cardiovascular disease[J].Front Cardiovasc Med, 2025, 12: 1620669.

[58]

Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to akt-dependent cell growth[J].Cell Metab, 2008, 8(3): 224-236.

[59]

Zhao YH.Resveratrol improves lipid metabolism in diabetic nephropathy rats[J].Front Biosci, 2020, 25(10): 1913-1924.

[60]

Sheng H, Zhang D, Zhang J, et al. Kaempferol attenuated diabetic nephropathy by reducing apoptosis and promoting autophagy through AMPK/mTOR pathways[J].Front Med, 2022, 9: 986825.

[61]

王鑫, 吴巧敏, 黄超颖, 等. 黄芪-苍术改善糖尿病肾病糖脂代谢的网络药理学研究[J].天然产物研究与开发, 2019, 31(12): 2051-2057.

[62]

Zhang MY, Zheng SQ.Network pharmacology and molecular dynamics study of the effect of the Astragalus-Coptis drug pair on diabetic kidney disease[J].World J Diabetes, 2024, 15(7): 1562-1588.

[63]

李新宝, 庞欣欣, 彭紫凝, 等. 基于生物信息学及动物实验对芪黄固肾通络方治疗糖尿病肾病的研究[J].世界中医药, 2024, 19(5): 615-622.

基金资助

北京市自然科学基金面上项目(7232326)

国家自然科学基金面上项目(82274489)

国家自然科学基金面上项目(82575000)

国家自然科学基金地区基金项目(82060849)

AI Summary AI Mindmap
PDF (1247KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉